Latest Immunohistochemistry Stories
TUCSON, Ariz., June 14, 2011 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, announced today that the FDA approved the INFORM HER2 Dual ISH DNA Probe cocktail assay (HER2 Dual ISH) for commercialization in the United States.
EXTON, Pa., March 29, 2011 /PRNewswire/ -- MorphotekÂ®, Inc., a subsidiary of Eisai Inc., announced today that it has entered into a collaboration and license agreement with Biocare Medical, LLC.
Lung cancer is considered the 6th most common cause of cancer deaths in the United States.
An inexpensive and rapid testing method can effectively identify a sub-group of never-smoking lung cancer patients whose tumors express a molecule associated with increased risk of disease progression or recurrence, US researchers have found.
Today a digitized, or computerized, form of immunohistochemistry (IHC) is revolutionizing the clinical pathology industry, helping pathologists make diagnoses with improved accuracy, efficiency and speed are invaluable to the doctors and their patients who rely on pathology results.
ROCKVILLE, Md., Jan. 20, 2011 /PRNewswire/ -- OriGene Technologies, Inc. has recently achieved a significant milestone in its quest for developing an assay for every human protein through the release of 1,500 mouse monoclonal antibodies under the TrueMAB brand.
BRANFORD, Conn., Nov. 12, 2010 /PRNewswire/ -- HistoRx, Inc. (privately held), a diagnostics company, announced the launch and first commercial sale this week of clinical diagnostic assays based on AQUAÂ® technology. Genoptix, Inc.
BURLINGAME, Calif., Aug. 9 /PRNewswire/ -- Epitomics, Inc., the rabbit monoclonal antibody company, announces today the launch of EP Clone(TM) Rabbit Monoclonal Antibodies and their detection systems for pathology applications.
ALISO VIEJO, Calif., June 16 /PRNewswire-FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that Neal S. Goldstein, M.D., has been named the Company's Director of Surgical Pathology.
NEW HAVEN, Conn., May 12 /PRNewswire/ -- HistoRx , Inc., announced today that the U.S. Patent and Trademark Office has granted a patent protecting the company's methods for determining a cancer patient's prognosis based on sub-cellular localization of biomarkers. U.S. Patent No.
- In medieval musical notation, a sign or neume denoting a shake or trill.